# Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

> **NCT05209308** · PHASE2 · WITHDRAWN · sponsor: **MEI Pharma, Inc.**

## Conditions studied

- CLL

## Interventions

- **DRUG:** Zandelisib
- **DRUG:** Rituximab
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05209308
- **Lead sponsor:** MEI Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-11-22
- **Primary completion:** 2023-03-15
- **Final completion:** 2023-03-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Discontinuation of zandelisib development
- **Last updated:** 2023-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05209308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05209308, "Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05209308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*